Pharma: Page
-
Scott Olson via Getty Images
Obesity drugsLilly, battling skepticism, reinforces GLP-1 pill’s case with new study data
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.
By Kristin Jensen • Oct. 15, 2025 -
William Walker/BioPharma Dive
Sponsored by Pearson[Podcast] The Progress Profile: Alzheimer’s Research in Focus
Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.
By BioPharma Dive's studioID • Oct. 15, 2025 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Courtesy of Johnson & Johnson
J&J plans to spin out orthopedics business
CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.
By Ricky Zipp • Oct. 14, 2025 -
Getty Images
Immune resetBristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
By Jonathan Gardner • Oct. 10, 2025 -
Getty Images
Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease
The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.
By Delilah Alvarado • Oct. 8, 2025 -
Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
Peter Marks, former top FDA vaccine official, joins Eli Lilly
Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.
By Jonathan Gardner • Oct. 7, 2025 -
Alamy
AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer
The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.
By Delilah Alvarado • Oct. 6, 2025 -
Alamy
Amgen claims ‘landmark’ study result that could widen heart drug’s use
In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.
By Jonathan Gardner • Oct. 2, 2025 -
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.
By Michael Gibney • Oct. 2, 2025 -
Jacob Bell/BioPharma Dive
Takeda, in reversal, abandons cell therapy research
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.
By Delilah Alvarado • Oct. 1, 2025 -
ASCO / Nick Agro
The top biopharma conferences remaining in 2026
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for the rest of 2026.
By Ben Fidler • Updated June 25, 2026 -
Win McNamee via Getty Images
Trump administrationTrump, Pfizer drug pricing deal short on details, possible impact
A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.
By Jonathan Gardner • Sept. 30, 2025 -
Getty Images
Obesity drugsMetsera strengthens case for Pfizer buyout with latest study data
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.
By Jonathan Gardner • Sept. 30, 2025 -
Courtesy of GSK Flickr page
Emma Walmsley, big pharma’s first female CEO, to depart GSK
Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.
By Jonathan Gardner • Sept. 29, 2025 -
Courtesy of Genmab A/S
Genmab to acquire closely watched cancer drug in $8B Merus buyout
The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when added to Merck’s widely used immunotherapy Keytruda.
By Delilah Alvarado • Sept. 29, 2025 -
Getty Images
Pharma reshoringKey exemptions could limit impact of Trump’s pharmaceutical tariffs
Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.
By Jonathan Gardner • Sept. 26, 2025 -
Andrew Harnik via Getty Images
Pharma reshoringTrump sets tariffs on pharmaceuticals, trucks, furniture
The new levies, ranging from 25% to 100%, will go into effect Oct. 1, the president said Thursday.
By Phil Neuffer • Sept. 25, 2025 -
Scott Olson via Getty Images
Lilly’s oral SERD gets FDA nod in advanced breast cancer
The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.
By Ben Fidler • Sept. 25, 2025 -
Scott Olson via Getty Images
Obesity drugsLilly stops trial of muscle-sparing obesity drug
Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.
By Jonathan Gardner • Sept. 25, 2025 -
Courtesy of Sanofi
Emerging biotechSanofi Ventures banks $625M to back young biotechs, digital health startups
The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.
By Gwendolyn Wu • Sept. 24, 2025 -
Getty Images
Trump administrationFDA, in unusual step, aims to repurpose old GSK drug as autism treatment
After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling more than two decades ago — for a condition associated with autism.
By Kristin Jensen • Sept. 23, 2025 -
Jacob Bell/BioPharma Dive
Obesity drugsPfizer buys back into obesity drug chase with $4.9B Metsera deal
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.
By Jonathan Gardner • Sept. 22, 2025 -
Elijah Nouvelage / Stringer via Getty Images
VaccinesCDC panel recommends splitting measles, varicella shots
The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children program, citing panelists’ confusion the day before.
By Jonathan Gardner • Updated Sept. 19, 2025 -
Getty Images
Pharma reshoring
GSK ups US investment with $30B spending plan
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.
By Ned Pagliarulo • Sept. 17, 2025 -
Getty Images
News roundupLilly, Novo showcase new obesity drug data; Fasenra falls short in COPD
Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”
By BioPharma Dive staff • Sept. 17, 2025
Previous
